chevron_leftBack
As of 24 April 2025, Pharming Group N.V. has a market cap of $582.15M USD, ranking #11050 globally and #65 in the Netherlands. It ranks #1083 in the Healthcare sector, and #281 in the Biotechnology industry.
Key Stats
Market Cap
$582.15MUSD
511.58M EUR
Enterprise Value
$521.06MUSD
457.9M EUR
Revenue (TTM)
$326.67MUSD
287.07M EUR
EBITDA (TTM)
$3.54MUSD
3.11M EUR
Net Income (TTM)
-$13.02MUSD
-11.44M EUR
EBITDA Margin
1.1%
Profit Margin
-4%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Fabrice Chouraqui
open_in_new
Employees
404
Founded
1988
Website
pharming.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 6.1% | -0.5% | -16% | -19% | -17% | -22% |
Upcoming Earnings
Earnings Date
Thu, May 8
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
PHARM
Pharming Group
ISIN: NL0010391025
Shares Out.:
Shares Outstanding:
680.309M1
Shares Float:
667.463M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.7480 EUR | |
|
0QCO
Pharming Group
ISIN: NL0010391025
|
0.7005 EUR | |
|
NASDAQ
MIC: XNAS
|
PHAR
Pharming Group ADR
ISIN: US71716E1055
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
8.27 USD |
|
PHGUF
Pharming Group
ISIN: NL0010391025
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.9000 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
